Jaguar Health

Jaguar Health R&D per Employee

The R&D Spending per Employee of Jaguar Health (JAGX) as of Nov 21, 2026 is 531,191.49 USD. In the previous year, R&D Spending per Employee was 351,957.45 USD — a change of 50.92% (higher).

R&D per Employee

531,191.49USD

YoY

50.92%

Last updated:

R&D Spending per Employee of Jaguar Health is 2025 531,191.49 USD. R&D Spending per Employee of Jaguar Health was 2024 351,957.45 USD. It decreases by 50.92% higher compared to the previous year.

The Jaguar Health R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
109,675.49 USD
Jan 1, 2019
123,829.79 USD
Jan 1, 2020
136,446.81 USD
Jan 1, 2021
320,829.79 USD
Jan 1, 2022
375,468.09 USD
Jan 1, 2023
395,659.57 USD
Jan 1, 2024
351,957.45 USD
Jan 1, 2025
531,191.49 USD
The Jaguar Health R&D per Employee history
YEARR&D per EmployeeYoY
531,191.49USD+50.92%
351,957.45USD-11.05%
395,659.57USD+5.38%
375,468.09USD+17.03%
320,829.79USD+135.13%
136,446.81USD+10.19%
123,829.79USD+12.91%
109,675.49USD+20.74%
90,839.47USD-40.76%
153,337.53USD+11.29%
137,784.06USD+53.44%
89,794.43USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jaguar Health Stock analysis

What does Jaguar Health do? Jaguar Health, Inc. generates revenue through the commercialization of gastrointestinal pharmaceuticals, primarily Mytesi for HIV/AIDS patients on antiretroviral therapy. The company markets Mytesi, Canalevia, Equilevia, Neonorm Calf, and Neonorm Foal, targeting both human prescription and animal health segments. Its subsidiary Napo Pharmaceuticals, Inc. develops plant-derived products from rainforest traditions, focusing on sustainable sourcing for global markets. Revenue streams are derived from direct sales to healthcare providers and veterinary suppliers in the human and animal gastrointestinal health sectors. The company's products serve distinct market segments: Mytesi addresses human prescription needs for HIV/AIDS-related diarrhea, while Canalevia, Equilevia, Neonorm Calf, and Neonorm Foal cater to veterinary use for horses, calves, and foals. Napo Pharmaceuticals, Inc. supports the development of rainforest-sourced gastrointestinal treatments, aligning with the company's focus on sustainable plant-based solutions. Sales are directed toward medical professionals and veterinary practitioners globally. Jaguar Health, Inc. monetizes its pharmaceutical portfolio through prescription drug sales and veterinary product distribution. Mytesi is the primary revenue driver for human gastrointestinal health, while animal health products like Neonorm Calf and Neonorm Foal target livestock and equine markets. The company's business model emphasizes sustainable plant-derived ingredients, leveraging traditional rainforest knowledge to differentiate its offerings in both human and animal health markets. Jaguar Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jaguar Health stock

R&D Spending per Employee of Jaguar Health is 531,191.49 USD in 2025.

R&D Spending per Employee of Jaguar Health changed from 351,957.45 USD to 531,191.49 USD, representing a 50.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Jaguar Health since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Jaguar Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Jaguar Health

All Key Metrics — Jaguar Health